Evidence map›Paper›PMID 33814842›Full record

ArticleIndian journal of surgical oncology2021

A Prospective Study on Metronomic Scheduling of Non-chemotherapeutic Drugs in Advanced Epithelial Ovarian Cancers.

Shruthi Shivdas, T Rajatharangani, Praveen S Rathod, V R Pallavi, Uttam D Bafna, C R Vijay, K Shobha, Rajashekar Kundargi

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Indian journal of surgical oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 100% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 0 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Shruthi ShivdasDepartment of Gynaecologic Oncology, Kidwai Memorial Institute of Oncology campus, No. 5, AB Type, Block- 1, Dr M H Marigowda Road, Bangalore, 560029 India.
T RajatharanganiDepartment of Gynaecologic Oncology, Kidwai Memorial Institute of Oncology campus, No. 5, AB Type, Block- 1, Dr M H Marigowda Road, Bangalore, 560029 India.
Praveen S RathodDepartment of Gynaecologic Oncology, Kidwai Memorial Institute of Oncology campus, No. 5, AB Type, Block- 1, Dr M H Marigowda Road, Bangalore, 560029 India.
V R PallaviDepartment of Gynaecologic Oncology, Kidwai Memorial Institute of Oncology campus, No. 5, AB Type, Block- 1, Dr M H Marigowda Road, Bangalore, 560029 India.
Uttam D BafnaDepartment of Gynaecologic Oncology, Kidwai Memorial Institute of Oncology campus, No. 5, AB Type, Block- 1, Dr M H Marigowda Road, Bangalore, 560029 India.
C R VijayDepartment of Biostatistics, Kidwai Memorial Institute of Oncology, Bangalore, India.
K ShobhaDepartment of Gynaecologic Oncology, Kidwai Memorial Institute of Oncology campus, No. 5, AB Type, Block- 1, Dr M H Marigowda Road, Bangalore, 560029 India.
Rajashekar KundargiDepartment of Gynaecologic Oncology, Kidwai Memorial Institute of Oncology campus, No. 5, AB Type, Block- 1, Dr M H Marigowda Road, Bangalore, 560029 India.
Kidwai Memorial Institute of Oncology · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The objectives of this study are to assess the role of non-chemotherapeutic combination of drugs as maintenance therapy, after standard treatment, for advanced epithelial ovarian cancers (EOC) and to determine the recurrence-free survival (RFS) and cancer-specific survival (CSS). One hundred women with advanced high-grade EOC who had completed standard treatment by primary/interval debulking surgery followed by adjuvant chemotherapy were randomised to either receive (study group) or not to receive (control group) the non-chemotherapeutic maintenance therapy (oral metformin, anastrozole, aspirin, atorvastatin, vitamin D, injection zoledronic acid). Both groups were followed up, and trends of RFS and CSS were analysed. One hundred patients were analysed. Median RFS was 18 months (95% CI: 13-24) in study group versus 16 (95% CI: 14-20) in the control group ( SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s13193-020-01261-w.

Indexed as

Advanced EOCDrug repositioningMaintenance treatmentMetronomicNon-chemotherapeutic drugs

Identifiers

PMID33814842
PMCPMC7960812
OpenAlexW3118834399

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.